Glenmark Pharma Q1 FY27 Revenue Jumps 23.1% to ₹40,185 Million

Glenmark Pharmaceuticals Ltd. reported a strong first quarter for FY27, with consolidated revenue soaring by 23.1% year-on-year to ₹40,185 million. This growth was driven by robust performance across key markets, including a 15.5% rise in India Formulations, a significant 41.1% surge in North America (partially due to deferred out-licensing income), and strong double-digit growth in Europe and Emerging Markets. EBITDA increased by 38.6% to ₹8,048 million, with an improved EBITDA margin of 20.03%. Profit After Tax (PAT) stood at ₹4,828 million, reflecting a PAT margin of 11.8%. The company highlighted broad-based growth and strong execution, with Chairman & Managing Director Glenn Saldanha expressing confidence in strengthening core businesses and expanding specialty and innovation-led platforms.